MedPage Today on MSN
New FDA-Approved Option for HER2-Mutated Lung Cancer
The FDA announced accelerated approval of sevabertinib (Hyrnuo) for HER2-positive non-small cell lung cancer (NSCLC).
Amgen's Imdelltra received full approval from the Food and Drug Administration for use in patients with lung cancer. The biotechnology company said Wednesday Imdelltra received approval for adult ...
The U.S. Food and Drug Administration on Wednesday said it has approved Bayer's drug for patients with a type of lung cancer ...
13h
If you experience these symptoms repeatedly, you could have lung cancer: “You should see a doctor”
A health campaign urges the public to pay closer attention to subtle warning signs that often go unnoticed in the earliest ...
The Food and Drug Administration (FDA) granted traditional approval to Imdelltra (tarlatamab-dlle) for adult patients with ...
Approximately 20% of new lung cancer diagnoses occur in nonsmokers in the U.S., according to The Ohio State University ...
New artificial intelligence technology is helping diagnose the U.S.’s most deadly cancer sooner, greatly improving the ...
The FDA has approved Hyrnuo for some with locally advanced or metastatic non-squamous non–small cell lung cancer with ...
Nearly 8% of Ohioans live with chronic obstructive pulmonary disease (COPD), a long-term, progressive lung disease that causes difficulty breathing. In fact, Ohio is among the states in the country ...
New Clinical Trial Site Added for Clinical Studies of Reqorsa® Gene Therapy to Treat Lung Cancer Acclaim-1 and Acclaim-3 ...
Andamertinib showed promising efficacy in NSCLC patients with EGFR exon 20 mutations, achieving a 42.7% ORR in the 240-mg cohort.
Among adults with COPD, the likelihood for having mucus plugs on CT can be determined using a tool that considers 11 “readily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback